Clinical Trial Update: Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating the combination of ipilimumab, nivolumab, and sacituzumab govitecan in metastatic cisplatin-ineligible urothelial carcinoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• TRODELVY (sacituzumab govitecan)
• Yervoy (ipilimumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Urothelial Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING